Reports Q3 revenue $196.6M, consensus $210.19M. “I am very proud of the progress all of our teams made this quarter,” said Matthew Klein, CEO. “The recent Royalty Pharma transaction and restructuring initiatives that we implemented have put the company on a strong financial footing. We believe we are well positioned to deliver on our most promising opportunities for growth, including the potential sepiapterin revenue opportunity of more than $1 billion and the PTC518 HD program.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PTCT:
- PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results
- PTC Therapeutics signs royalty agreement with Royalty Pharma for Evrysdi
- PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion
- e.l.f. Beauty upgraded, AutoZone downgraded: Wall Street’s top analyst calls
- PTC Therapeutics cut to Hold at Truist on financing and development hurdles